Glycoengineering using Leishmania cells
AssigneeLimmatech Biologics AG
InventorsManuela Mally, Amirreza Faridmoayer, Rainer Follador, Anke Judith Harsman
Life of this patent
Estimating the term…
Abstract
The present application relates to Leishmania cells genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the Leishmania cell is reduced or eliminated. The formation of the O-linked GlcNAc may be catalyzed in the Leishmania cell prior to said genetic engineering by at least one N-acetylglucosamine (GlcNAc)-transferase. Also provided herein are methods of making a polypeptide using a Leishmania cell described herein and polypeptides produced by the methods provided herein.
Claims20
A Leishmania cell genetically engineered such that the formation of an O-linked N-acetylglucosamine (GlcNAc) on a polypeptide in the Leishmania cell is reduced or eliminated, wherein a gene encoding at least one O-linked GlcNAc-transferase of the Leishmania cell is functionally inactivated, downregulated, deleted, mutated, or overexpressed.
Dependencies are inferred from the claim text.